Pune, India, April 11, 2019 (GLOBE NEWSWIRE) -- The Anti-hypertensive Drugs Market is expected to experience a moderate CAGR of 2.67% during the forecast period (2018-2023) with the valuation touching USD 41,123.2 million by the end of 2023.
An uptick in the lifestyle, triggered by jet-speed urbanization and industrialization, at times reveal a few clefts. The change takes people afar from the root which can adversely impact the body. One such is hypertension or high blood pressure. If allowed to persist longer, then it has the potential to lead to much more demanding diseases such as heart failure, stroke, peripheral vascular disease, chronic kidney disease, and others. To counter the disease, anti-hypertensive drugs have been introduced by various drug manufacturers. These drugs are primarily chemicals that can lower high blood pressure or tension and curb chances of contracting myocardial infarction or stroke.
Key Players Locking Horns:
The anti-hypertensive drugs market is densely packed with several market titans who have engaged long in strategic battles to take over the market. This has created a perfect ambience for the anti-hypertensive drugs market to move forward. Companies such as Pfizer, Inc. (U.S.), AstraZeneca (U.K.), Novartis AG (Switzerland), Daiichi Sankyo Company, Ltd. (Japan), United Therapeutics Corporation (U.S.), Sanofi S.A. (France), Johnson & Johnson Services, Inc. (U.S.), Merck KGaA (Germany), Takeda Pharmaceutical Company (Japan), Boehringer Engelheim GmbH (Germany), and Bayer AG (Germany) are impacting the market with their tactical moves.
Request Free Sample at: https://www.marketresearchfuture.com/sample_request/2347
Future Market Factors:
At present, the anti-hypertensive drugs market is substantially big and the coming days promise of a moderate growth with factors such as government initiatives and introduction of generics to back it up. Hypertension is a disease that is becoming quite common, even youths are displaying symptoms of it. This has led to initiatives undertaken by governments and NGOs across the globe to make people aware of symptoms and involve them in taking necessary measures. Several programs are getting planned to build up a robust network which integrates patients as a part of the entire setup. At the same time, the anti-hypertensive drugs market is getting traction due to the mass production of generic drugs which has lowered the cost of treatment substantially.
Segmentation:
The anti-hypertensive drugs market can be judged on the basis of several segmental analysis that convey both volume-wise and value-wise data. These segments are type, therapeutic class, and distribution channel.
Based on the type, the anti-hypertensive drugs market can be segmented into primary and secondary hypertension. As of 2017, the primary segment scored the most, a growth that was triggered by genetic factors and insulin resistance. Lifestyle changes can also be considered an elemental force in pushing the segment forward.
Based on the therapeutic class, the anti-hypertensive drugs market includes calcium blockers, ACE inhibitors, vasodilators, diuretics, renin inhibitors, beta-adrenergic blockers, ARBs, and others. The diuretics segment is expected to top the market in the coming years but the ACE inhibitors are expected to receive exponential CAGR during the forecast period.
By distribution channels, the anti-hypertensive drugs market can rely on online pharmacy, e- commerce websites & online drug stores, hospital pharmacy, retail pharmacy, and others. The retail pharmacy segment is cruising ahead with substantial market lead and prospect.
Regional Challenges:
The anti-hypertensive drugs market depends mostly on the Americas, Europe, Asia Pacific (APAC), and the Middle East & Africa (MEA). Region-specific analysis of the market reveals growth pockets that can be of great benefit for market players.
Presence of several major pharmaceuticals is just one of the many factors that is contributing substantially to the growth of the North American market. Other factors such as high awareness and better medical facilities are amply backing the region’s global supreme position. Structurally, the region is way ahead of its peers which is partnering well with reimbursement policies.
Europe has drivers similar to North America. The revenue that the regional market is generating is also helping them into developing strategies for further market expansion. For the companies in this region, the APAC is fast emerging as an alluring space where they are expanding their setups to increase the profit margin.
The APAC region gains mostly from its vast population which significantly possesses one of the largest patient pools globally. At the same time, several countries in the region are leaving out their cocoon to emerge as prominent economies. This has triggered in an overhauling of the prevalent setup. Healthcare sector is in the frontline that is gaining maximum benefits of such initiatives. As a host for foreign players, the region is making strategies well to take the market forward.
Browse the market data and information spread across 124 pages with 96 data tables and 17 figures of the report “Anti-Hypertensive Drugs Market- Forecast 2018-2023” in-depth alongside table of content (TOC) at: https://www.marketresearchfuture.com/reports/anti-hypertensive-drugs-market-2347
Changes to Change Trends:
In a recent article of the American Journal of Physiology, researchers claimed that lower level of zinc in the body can alter kidney function and increase blood pressure. The lack of it would affect kidney’s handling of sodium which would then trigger irregularity in proteins.
Hypertension Service and Hypertension Specialty Clinic, Brigham, recently started operating by providing their patients with a Bluetooth device and instructing them to check their blood pressure twice daily. Such an initiative lowered the hypertension symptoms in maximum patients as it allows doctors to alter medications in time. The process is cost-effective and uses precious hours to save lives.
Browse Related Reports:
Anti-Ageing Drugs Market by Drug Class (Serums and Supplements, Antioxidants and Enzymes, Stem Cells, Drugs) by Applications (Skin and Hair, Skeletal and Muscles, Age Related Disorders) - Global Forecast till 2023
https://www.marketresearchfuture.com/reports/anti-ageing-drugs-market-3504
Anti-viral Drugs Market Information by Application (Hepatitis, HIV/AIDS, Herpes, Influenza), Mechanism of Action (Nucleotide Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors), and Region - Forecast to 2022
https://www.marketresearchfuture.com/reports/anti-viral-drugs-market-2454
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services.
MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.